Immunome, Inc. Hits Day High with 16.4% Surge in Stock Price

Immunome, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant activity today, gaining 16.4% as of October 6, 2025. The stock reached an intraday high of USD 14.48, reflecting a strong performance compared to the S&P 500, which saw a minimal increase of 0.01% on the same day.
Over the past week, Immunome has surged by 27.07%, and its one-month performance stands at an impressive 36.98%. Year-to-date, the stock has risen by 35.69%, outperforming the S&P 500's 14.18% gain. Notably, the company has reported a net profit of USD -85.04 million for the first half of the year, marking a turnaround after five consecutive quarters of negative results.

Despite the positive momentum, Immunome's financials indicate a challenging landscape, with a negative EBITDA and a return on equity of -66.22%. However, the company benefits from high institutional holdings at 100%, suggesting strong confidence from larger investors. The reduction in raw material costs by 14.94% year-over-year may also contribute to its current performance.